155 related articles for article (PubMed ID: 2866336)
1. Placebo-controlled, double-blind, two-centre trial of ketanserin in intermittent claudication.
Bounameaux H; Holditch T; Hellemans H; Berent A; Verhaeghe R
Lancet; 1985 Dec; 2(8467):1268-71. PubMed ID: 2866336
[TBL] [Abstract][Full Text] [Related]
2. Placebo-controlled double-blind trial of ketanserin in treatment of intermittent claudication.
De Cree J; Leempoels J; Geukens H; Verhaegen H
Lancet; 1984 Oct; 2(8406):775-9. PubMed ID: 6148522
[TBL] [Abstract][Full Text] [Related]
3. Randomized placebo-controlled, double-blind trial of ketanserin in claudicants. Changes in claudication distance and ankle systolic pressure. PACK Claudication Substudy.
Circulation; 1989 Dec; 80(6):1544-8. PubMed ID: 2688971
[TBL] [Abstract][Full Text] [Related]
4. Acute effect of ketanserin on the leg perfusion assessed by Doppler pressure measurements and 201Tl scintigraphy in patients with intermittent claudication.
Bounameaux H; Devos P; Verhaeghe R
J Cardiovasc Pharmacol; 1985; 7(6):1083-6. PubMed ID: 2418292
[TBL] [Abstract][Full Text] [Related]
5. The PACK trial: morbidity and mortality effects of ketanserin. Prevention of Atherosclerotic Complications.
Verstraete M
Vasc Med; 1996; 1(2):135-40. PubMed ID: 9546928
[TBL] [Abstract][Full Text] [Related]
6. Ketanserin in intermittent claudication. A double-blind placebo-controlled study.
Clement DL; Duprez D; Van Wassenhove A; Brusselmans F
Int Angiol; 1989; 8(2):92-6. PubMed ID: 2681451
[TBL] [Abstract][Full Text] [Related]
7. Ketanserin in intermittent claudication: effect on walking distance, blood pressure, and cardiovascular complications.
Thulesius O; Lundvall J; Kroese A; Stranden E; Hallböök T; Brunes L; Gjöres JE; Akesson H; Einarsson E; Ohlin P
J Cardiovasc Pharmacol; 1987 Jun; 9(6):728-33. PubMed ID: 2442541
[TBL] [Abstract][Full Text] [Related]
8. Placebo-controlled trial of ketanserin in the treatment of intermittent claudication.
Cameron HA; Waller PC; Ramsay LE
Angiology; 1987 Jul; 38(7):549-55. PubMed ID: 3304029
[TBL] [Abstract][Full Text] [Related]
9. Randomized placebo-controlled, double-blind trial of ketanserin in treatment of intermittent claudication.
Walden R; Bass A; Rabi I; Adar R
J Cardiovasc Surg (Torino); 1991; 32(6):737-40. PubMed ID: 1752890
[TBL] [Abstract][Full Text] [Related]
10. Effect of ketanserin on macrocirculatory and microcirculatory blood flow in patients with intermittent claudication. A prospective randomized study.
Beckers RC; Jörning PJ; Slaaf DW; Reneman RS; Jacobs MJ
Eur J Clin Pharmacol; 1989; 37(3):295-6. PubMed ID: 2693113
[TBL] [Abstract][Full Text] [Related]
11. A double-blind, placebo-controlled study of ketanserin in patients with Prinzmetal's angina. Evidence against a role for serotonin in the genesis of coronary vasospasm.
De Caterina R; Carpeggiani C; L'Abbate A
Circulation; 1984 May; 69(5):889-94. PubMed ID: 6705164
[TBL] [Abstract][Full Text] [Related]
12. Effect of ketanserin in the treatment of patients with intermittent claudication: results from 13 placebo-controlled parallel group studies.
Clement DL; Duprez D
J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S89-95. PubMed ID: 2446082
[TBL] [Abstract][Full Text] [Related]
13. Antihypertensive action and serotonin-induced platelet aggregation during long-term ketanserin treatment in hypertensive patients.
Amery A; Fagard R; Fiocchi R; Lijnen P; Staessen J; Vermylen J
J Cardiovasc Pharmacol; 1984; 6(1):182-5. PubMed ID: 6199602
[TBL] [Abstract][Full Text] [Related]
14. Platelet function during long-term treatment with ketanserin of claudicating patients with peripheral atherosclerosis. A multi-center, double-blind, placebo-controlled trial. The PACK Trial Group.
Thromb Res; 1989 Jul; 55(1):13-23. PubMed ID: 2528841
[TBL] [Abstract][Full Text] [Related]
15. Clinical and microcirculatory effects of transcutaneous CO2 therapy in intermittent claudication. Randomized double-blind clinical trial with a parallel design.
Fabry R; Monnet P; Schmidt J; Lusson JR; Carpentier PH; Baguet JC; Dubray C
Vasa; 2009 Aug; 38(3):213-24. PubMed ID: 19736632
[TBL] [Abstract][Full Text] [Related]
16. Double-blind placebo-controlled trial of buflomedil in intermittent claudication.
Fonseca V; Mikhailidis DP; Barradas MA; Jeremy JY; Gracey L; Dandona P
Int J Clin Pharmacol Res; 1988; 8(5):377-81. PubMed ID: 3229875
[TBL] [Abstract][Full Text] [Related]
17. The effect of a combined administration of ridogrel and ketanserin in patients with intermittent claudication.
De Cree J; Geukens H; Gutwirth P; De Clerck F; Vercammen E; Verhaegen H
Int Angiol; 1993 Mar; 12(1):59-68. PubMed ID: 8376914
[TBL] [Abstract][Full Text] [Related]
18. Drug treatment of claudication: vasodilators, hemorrheologic agents, and antiserotonin drugs.
Taylor LM; Porter JM
J Vasc Surg; 1986 Feb; 3(2):374-81. PubMed ID: 2935646
[No Abstract] [Full Text] [Related]
19. The effect of ketanserin on blood pressure and biochemical parameters in treated patients with essential hypertension.
Wing LM; Chalmers JP; West MJ; Bune AJ; Ayres B; Graham JR
Clin Exp Hypertens A; 1984; 6(6):1107-17. PubMed ID: 6146414
[TBL] [Abstract][Full Text] [Related]
20. Comparison of blood pressure ratio by Doppler velocimetry and by plethysmography during treatment with ketanserin, a 5-HT2 receptor antagonist: a measure of improved collateral and microcirculatory flow.
De Cree J; Leempoels J; Geukens H; Verhaegen H
J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S92-4. PubMed ID: 2412069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
